

1996 Cumulative Table of Contents Psychopharmacology Bulletin

Vol. 32, No. 1—1996

1995 NCDEU Symposia, Posters, and Free Communications

- 1** Editor's Note—*Matthew V. Rudorfer*

Plenary Panel: Ethical Dilemmas in Clinical Research

- 5** Introductory Remarks—*Rex Cowdry*
- 7** Ethical Principles and Informed Consent: An NIMH Perspective—*David Shore*
- 11** Challenges to the Ethicality of Clinical Research—*Paul Leber*
- 15** Ethical Dilemmas in Clinical Research—*Thomas Detre*
- 19** Ethical Dilemmas in Clinical Research With Human Subjects: An Investigator's Perspective—*Jeffrey A. Lieberman*

Free Communications and Poster Session Papers

Depression

- 27** Fluoxetine and Norfluoxetine Serum Concentrations and Clinical Response in Weekly Versus Daily Dosing—*William J. Burke, Shelton E. Hendricks, Delores McArthur-Campbell, Daniel Jacques, and Todd Stull*
- 33** Improvement in Subjective Work Performance After Treatment of Chronic Depression: Some Preliminary Results—*Stan N. Finkelstein, Ernst R. Berndt, Paul E. Greenberg, Rod A. Parsley, James M. Russell, Martin B. Keller, and the Chronic Depression Study Group*

- 41** Sertraline in the Treatment of Premenstrual Dysphoric Disorder—*Kimberly A. Yonkers, Uriel Halbreich, Ellen Freeman, Candace Brown, and Teri Pearlstein*

Bipolar and Attention Deficit Disorders

- 47** Lithium Treatment of Bipolar Affective Disorders Under Naturalistic Followup Conditions—*Joseph F. Goldberg, Martin Harrow, and Andrew C. Leon*
- 55** Risperidone Therapy in Treatment Refractory Acute Bipolar and Schizoaffective Mania—*Martha Sajatovic, Sue Kim DiGiovanni, Bijan Bastani, Helen Hattab, and Luis F. Ramirez*
- 63** Differences in Thyroid Function Studies in Acutely Manic Adolescents With and Without Attention Deficit Hyperactivity Disorder (ADHD)—*Scott A. West, Kenji W. Sax, Sean P. Stanton, Paul E. Keck, Jr., Susan L. McElroy, and Stephen M. Strakowski*
- 67** Nicotine and Attention in Adult Attention Deficit Hyperactivity Disorder (ADHD)—*C. Keith Conners, Edward D. Levin, Elizabeth Sparrow, Sean C. Hinton, Drew Erhardt, Warren H. Meck, Jed E. Rose, and John March*

Schizophrenia

- 75** Effect of Varying Haloperidol Plasma Levels on Negative Symptoms in Schizophrenia and Schizoaffective Disorder—*Jan Volavka, Thomas B. Cooper, Pál Czobor, and Morris Meisner*

- 81** A Comparison of an Atypical and Typical Antipsychotic, Zotepine Versus Haloperidol in Patients With Acute Exacerbation of Schizophrenia: A Parallel-Group Double-Blind Trial—*Michel Petit, Joher Raniwalla, Jack Tweed, Eric Leutenegger, Sonia Dollfus, and Finian Kelly*
- 89** Obsessive-Compulsive Symptoms in Schizophrenia: A Comparison of Olanzapine and Placebo—*Robert W. Baker, Donna Ames, Daniel S.G. Umbricht, K.N. Roy Chengappa, and Nina R. Schooler*
- 95** Regional Cerebral Blood Flow Changes Associated With Risperidone Treatment in Elderly Schizophrenia Patients: A Pilot Study—*Ileana Berman, Amalia Merson, Cecile Sison, Edward Allan, Clara Schaefer, Mordechai Loberboym, and Miklos F. Losonczy*
- 101** Serotonin-Mediated Increase in Cytosolic $[Ca^{2+}]$ in Platelets of Risperidone-Treated Schizophrenia Patients—*Larry Ereshefsky, Cara Riesenman, Janet E. True, and Martin Javors*
- 107** Plasma Prolactin in Schizophrenia Subjects Treated With SeroquelTM (ICI 204,636)—*Mark B. Hamner, Lisa A. Arvanitis, Barbara G. Miller, Christopher G.G. Link, and Walter W. Hong*
- 111** The Treatment of Clozapine-Associated Agranulocytosis With Granulocyte Colony-Stimulating Factor (G-CSF)—*K.N. Roy Chengappa, Aziz Gopalani, Marcia K. Haught, Kathy McChesney, Robert W. Baker, and Nina R. Schooler*
- 123** Zotepine: Preclinical Tests Predict Antipsychotic Efficacy and an Atypical Profile—*Patricia L. Needham, Julie Atkinson, Michael J. Skill, and David J. Heal*

- 129** The Effects of Cyproheptadine on Vacuous Jaw Movements in Rats: A Comparison With Haloperidol and Clozapine—*R.E. Steinpreis, H.J. Kaczmarek, and A. Harrington*

Anxiety and Related Disorders

- 135** A Double-Blind Placebo-Controlled Trial Comparing Fluvoxamine and Imipramine in the Treatment of Panic Disorder With or Without Agoraphobia—*David Bakish, Cynthia L. Hooper, Marie-Josée Filteau, Yolande Charbonneau, George Fraser, Dixy Lee West, Christine Thibodeau, and Dayle Raine*
- 143** The Relationship of Plasma Imipramine and N-Desmethyylimipramine to Response in Panic Disorder—*Matig R. Mavissakalian and James M. Perel*
- 149** Predictors of Quality of Life in a Long-Term Followup Study in Panic Disorder Patients After a Clinical Drug Trial—*Heinz Katschnig, Michaela Amering, Jon M. Stolk, and James C. Ballenger*
- 157** Use of Receiver-Operator Characteristic (ROC) Curve Analysis to Evaluate Predictors of Response to Clomipramine Therapy—*Deborah L. Ackerman, Sander Greenland, and Alexander Bystritsky*
- 167** Drug Treatment of Obsessive-Compulsive Disorder (OCD): Long-Term Trial With Clomipramine and Selective Serotonin Reuptake Inhibitors (SSRIs)—*Luigi Ravizza, Giulio Barzega, Silvio Bellino, Filippo Bogetto, and Giuseppe Maina*
- 175** An Open Study of Buspirone Augmentation of Serotonin Reuptake Inhibitors in Body Dysmorphic Disorder—*Katharine A. Phillips*

Vol. 32, No. 2—1996

- 181** Editor's Note—*Matthew V. Rudorfer*

Ethnicity in the Pharmacologic Treatment Process

- 183** Socioecological and Sociocultural Variables in Psychopharmacological Research: Methodological Considerations—*Samuel M. Turner and Michele R. Cooley-Quille*
- 193** Increasing Ethnic Diversity and Managed Care: How Will They Influence Research Patient Recruitment in the Nineties?—*Charles S. Wilcox, Barbara B. Katz, DeAnn L. Morgan, Judy L. Morrissey, Alan L. Schneider, and Don F. DeFrancisco*
- 201** Women and Minorities Representation in Alcoholism Treatment Research—*Lauren D. Williams, Barbara J. Mason, Gloria Goldberg, and Robert B. Cutler*
- 205** The Evolving Science of Pharmacogenetics: Clinical and Ethnic Perspectives—*Keh-Ming Lin, Russell E. Poland, Yu-Jui Y. Wan, Michael W. Smith, and Ira M. Lesser*
- 219** Genetic Polymorphism of S-Mephenytoin 4'-Hydroxylation—*Harold I. Daniel and Timi I. Edeki*
- 231** Ethnic Considerations in the Pharmacotherapy of Mood Disorders—*Emile D. Risby*
- 235** Brain Imaging, Antidepressants, and Ethnicity: Preliminary Observations—*Ira M. Lesser, Michael W. Smith, Marcy Wohl, Ismael Mena, C. Mark Mehringer, and Keh-Ming Lin*
- 243** Relationship of Ethnicity and Gender to Schizophrenia and Pharmacology of Neuroleptics—*Dilip V. Jeste, Laurie A. Lindamer, Jovier Evans, and Jonathan P. Lacro*
- 253** Clozapine Dosage, Serum Levels, Efficacy, and Side-Effect Profiles: A Comparison of Korean-American and Caucasian Patients—*K. Traci Matsuda, Man Chul Cho, Keh-Ming Lin, Michael W. Smith, Alexander S. Young, and Jeffrey A. Adams*
- 259** Interethnic Psychopharmacologic Research in Children and Adolescents—*James J. Hudziak and Barbara Geller*
- 265** Ethnicity and Eating Disorders: Implications for Incidence and Treatment—*Kathleen M. Pike and B. Timothy Walsh*
- 275** Clinical Issues in the Pharmacotherapy of African-Americans—*William B. Lawson*
- 283** The Interaction of Ethnicity, Sociocultural Factors, and Gender in Clinical Psychopharmacology—*Karon Dawkins*

Vol. 32, No. 3—1996

- 291** Editor's Note—*Matthew V. Rudorfer*

- 293** Psychopharmacology in HIV-Positive Patients: Research Perspectives—*Benedetto Vitiello and Ellen S. Stover*

- 299** FDA MedWatch Report: Lithium and Neuroleptics in Combination: The Spectrum of Neurotoxicity—*Stephen A. Goldman*

- 311** A Curbstone Consult to Applicants for National Institute of Mental Health Grant Support—*A. John Rush, Christina M. Gullion, and Robert F. Prien*

Clinical Psychopharmacology

- 321** Utilization of Depot Neuroleptic Medication in Psychiatric Inpatients—*Leslie Citrome, Jerome Levine, and Baerbel Allingham*
- 327** Selegiline in Adults With Attention Deficit Hyperactivity Disorder: Clinical Efficacy and Safety—*Monique Ernst, Laura L. Liebenauer, Peter H. Jons, Daniel Tebeka, Robert M. Cohen, and Alan J. Zametkin*
- 335** A Double-Blind Trial of Low- and High-Dose Ranges of Gepirone-ER Compared With Placebo in the Treatment of Depressed Outpatients—*Charles S. Wilcox, James M. Ferguson, Jacqueline L. Dale, and Jon F. Heiser*

- 343** Lines of Therapeutic Research in Alzheimer's Disease—*A. Shvaloff, E. Neuman, and D. Guez*

Research Methodology and Data Interpretation

- 353** Evaluation of Screens for Mental Disorders in Primary Care: Methodological Issues—*Andrew C. Leon, Mark Olfson, Myrna M. Weissman, Laura Portera, and David V. Sheehan*
- 363** Randomized Trials in Single Subjects: The *N* of 1 Study—*Deborah J. Cook*
- 369** Comparing Speeds of Effectiveness of Two Treatments—*Robert A. Wolfe, Janet C. Wolfe, and A. Richard Entsuah*
- 377** Random Regression With Imputed Values for Dropouts—*John E. Overall, Ghassan Shobaki, and Joan Fiore*

Abstracts from the 1996 New Clinical Drug Evaluation Unit (NCDEU) Meeting

- 389** Free Communications
- 403** Poster Sessions

Vol. 32, No. 4—1996

**1996 NCDEU Annual Meeting
Workshops and Selected Papers**

- 541** Editor's Note—*Matthew V. Rudorfer*

**Polypharmacotherapy
Symposium II: Combined
Therapies in Affective and
Obsessive-Compulsive Disorders**

- 545** Introduction—*Robert L. Dufresne*
- 547** Issues in Polypharmacotherapy: Focus on Major Depression—*Robert L. Dufresne*
- 555** Pharmacokinetic and Pharmacodynamic Drug Interactions With Polypharmacotherapy of Treatment-Resistant Affective and Obsessive-Compulsive Disorders—*Stanley W. Carson*
- 569** Issues in the Monopharmacotherapy and Polypharmacotherapy of Obsessive-Compulsive Disorder—*Lyle K. Laird*
- 579** Polypharmacy in Bipolar I Disorder—*David A. Solomon, Gabor I. Keitner, Christine E. Ryan, and Ivan W. Miller*

**Pharmacological Treatment of
Somatization/Hypochondriasis**

- 589** Overview of Somatization: Diagnosis, Epidemiology, and Management—*Javier I. Escobar*
- 597** Pharmacologic Treatment of Body Dysmorphic Disorder—*Katharine A. Phillips*
- 607** The Pharmacotherapy of Hypochondriasis—*Brian A. Fallon, Franklin R. Schneier, Randall Marshall, Raphael Campeas, Donna Vermes, Debbie Goetz, and Michael R. Liebowitz*

Clinical Trials**A. Bipolar Disorder**

- 613** New Psychosocial Treatments for the Outpatient Management of Bipolar Disorder—*David J. Miklowitz, Ellen Frank, and Elizabeth L. George*
- 623** Comparison of Therapeutic Modalities for Mania—*Joyce G. Small, Marietta H. Klapper, Victor Milstein, Jon D. Marhenke, and Iver F. Small*

B. Major Depression

- 629** Venlafaxine or Bupropion Responders But Not Nonresponders Show Baseline Prefrontal and Paralimbic Hypometabolism Compared With Controls—*John T. Little, Terence A. Ketter, Tim A. Kimbrell, Aimee Danielson, Brenda Benson, Mark W. Willis, and Robert M. Post*
- 637** A Double-Blind, Placebo-Controlled Evaluation of the Effects of Orally Administered Venlafaxine on Sleep in Inpatients With Major Depression—*R. Luthringer, M. Toussaint, N. Schaltenbrand, P. Bailey, P.H. Danjou, D. Hackett, J.Y. Guichoux, and J.P. Macher*
- 647** Valproate as an Antidepressant in Major Depressive Disorder—*Lori L. Davis, David Kabel, Dhiren Patel, Amy D. Choate, Cynthia Foslien-Nash, George N.M. Gurguis, Gerald L. Kramer, and Frederick Petty*
- 653** Paroxetine Is a Novel Nitric Oxide Synthase Inhibitor—*Mitchell S. Finkel, Fouzia Laghrissi-Thode, Bruce G. Pollock, and Jing Rong*

- 659** A Double-Blind Comparison of Gepirone Extended Release, Imipramine, and Placebo in the Treatment of Outpatient Major Depression—*Alan D. Feiger*

C. Anxiety Disorders

- 667** Venlafaxine for Panic Disorder: Results from a Double-Blind, Placebo-Controlled Study—*Mark H. Pollack, John J. Worthington, Michael W. Otto, Kristin M. Maki, Jordan W. Smoller, Gisele G. Manfro, Richard Rudolph, and Jerrold F. Rosenbaum*
- 671** An Open Trial of Nefazodone in Adult Patients With Generalized Anxiety Disorder—*Dawson W. Hedges, Frederick W. Reimherr, Robert E. Strong, Corinne Huston Halls, and Cherie Rust*
- 677** Therapeutic Effect and Safety of Adjunctive Risperidone in Refractory Obsessive-Compulsive Disorder (OCD)—*Luigi Ravizza, Giulio Barzega, Silvio Bellino, Filippo Bogetto, and Giuseppe Maina*

Antipsychotics in Research and Clinical Settings

- 683** Clozapine's Effectiveness for Patients in State Hospitals: Results from a Randomized Trial—*Susan M. Essock, William A. Hargreaves, Nancy H. Covell, and John Goethe*

- 699** Longitudinal Analysis of Abnormal Involuntary Movements in Long-Term Clozapine-Treated Patients—*Mark T. Bunker, Roger W. Sommi, Steven C. Stoner, and Joy L. Switzer*

- 705** Development and Implementation of Drug Use Evaluation (DUE) Criteria for Risperidone in an Outpatient Psychiatric Setting—*John C. Shepski, Michael Z. Wincor, Mary A. Gutierrez, and Lawrence S. Gross*

- 721** Clinical and Economic Aspects of Risperidone Treatment in Adults With Mental Retardation and Behavioral Disturbance—*Rex S. Lott, Jill M. Kerrick, and Seth A. Cohen*

- 731** Glycinergic Augmentation of NMDA Receptor-Mediated Neurotransmission in the Treatment of Schizophrenia—*Uriel Heresco-Levy, Gail Silipo, and Daniel C. Javitt*

- 741** Magnetoencephalographic Assessment of Spontaneous Brain Activity in Schizophrenia—*José M. Cañive, Jeffrey David Lewine, James Chris Edgar, John T. Davis, Fernando Torres, Brian Roberts, David Graeber, William W. Orrison, and Vicente B. Tuason*

1996 Cumulative Table of Contents

1996 Cumulative Author Index

1996 Cumulative Keyword Index

